Tau monoclonal antibody generation based on humanized yeast models: Impact on tau oligomerization and diagnostics

Journal of Biological Chemistry

Volumn 290, Issue 7, 2015, Pages 4059-4074

  Rosseels, Joëlle ^a   Van Den Brande, Jeff ^a,b,c   Violet, Marie ^d,e,f   Jacobs, Dirk ^b   Grognet, Pierre ^c,j   Lopez, Juan ^e,g   Huvent, Isabelle ^e,g   Caldara, Marina ^a   Swinnen, Erwin ^a   Papegaey, Anthony ^d,e,f   Caillierez, Raphaëlle ^d,e,f   Buée Scherrer, Valerie ^d,e,f   Engelborghs, Sebastiaan ^h,i   Lippens, Guy ^e,g   Colin, Morvane ^d,e,f   Buée, Luc ^d,e,f   Galas, Marie Christine ^d,e,f   Vanmechelen, Eugeen ^b   Winderickx, Joris ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ADX NEUROSCIENCES   (Belgium)

^c FUJIREBIO INC   (Japan)

^d JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^e UNIV LILLE   (France)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

^h UNIVERSITY OF ANTWERP   (Belgium)

ⁱ Hospital Network Antwerp ZNA Middelheim and Hoge Beuken   (Belgium)

^j VETERINARY AND AGROCHEMICAL RESEARCH CENTRE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS; MONOCLONAL ANTIBODIES; NEURODEGENERATIVE DISEASES; OLIGOMERIZATION; OLIGOMERS; PROTEINS;

DIAGNOSTIC TOOLS; DISEASE ETIOLOGY; DISEASE PROGRESSION; HIGHER-ORDER; LOW ORDER;

ANTIBODIES;

EPITOPE; MONOCLONAL ANTIBODY; TAU PROTEIN; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; EPITOPE MAPPING; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OLIGOMERIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; YEAST; AMYLOID PLAQUE; ANIMAL; BAGG ALBINO MOUSE; BIOTINYLATION; BRAIN; CELL MEMBRANE; CEREBROSPINAL FLUID; CHEMISTRY; DISEASE COURSE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNIZATION; IMMUNOLOGY; IMMUNOPRECIPITATION; METABOLISM; NEUROFIBRILLARY TANGLE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PHOSPHORYLATION; SACCHAROMYCES CEREVISIAE; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; BIOTINYLATION; BLOTTING, WESTERN; BRAIN; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HIPPOCAMPUS; HUMANS; IMMUNIZATION; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MAGNETIC RESONANCE SPECTROSCOPY; MEMBRANE MICRODOMAINS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PLAQUE, AMYLOID; SACCHAROMYCES CEREVISIAE; TAU PROTEINS;

EID: 84922823517     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.627919     Document Type: Article

References (66)

1. Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., and Hof, P. R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130
2. Irwin, D. J., Cohen, T. J., Grossman, M., Arnold, S. E., Xie, S. X., Lee, V. M., and Trojanowski, J. Q. (2012) Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 135, 807-818
3. Wang, Y., Garg, S., Mandelkow, E. M., and Mandelkow, E. (2010) Proteolytic processing of tau. Biochem. Soc. Trans. 38, 955-961
4. Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M. L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., Schraen-Maschke, S., and Buée, L. (2008) Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev. Proteomics 5, 207-224
5. Irwin, D. J., McMillan, C. T., Toledo, J. B., Arnold, S. E., Shaw, L. M., Wang, L. S., Van Deerlin, V., Lee, V. M., Trojanowski, J. Q., and Grossman, M. (2012) Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch. Neurol. 69, 1018-1025
6. Le Bastard, N., Coart, E., Vanderstichele, H., Vanmechelen, E., Martin, J. J., and Engelborghs, S. (2013) Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologicallyconfirmed dementia. J. Alzheimers Dis. 33, 117-131
7. Berger, Z., Roder, H., Hanna, A., Carlson, A., Rangachari, V., Yue, M., Wszolek, Z., Ashe, K., Knight, J., Dickson, D., Andorfer, C., Rosenberry, T. L., Lewis, J., Hutton, M., and Janus, C. (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 27, 3650-3662
8. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Sengupta, U., Sarmiento, J., Troncoso, J., Jackson, G. R., and Kayed, R. (2012) Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946-1959
9. Patterson, K. R., Remmers, C., Fu, Y., Brooker, S., Kanaan, N. M., Vana, L., Ward, S., Reyes, J. F., Philibert, K., Glucksman, M. J., and Binder, L. I. (2011) Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J. Biol. Chem. 286, 23063-23076
10. Ward, S. M., Himmelstein, D. S., Lancia, J. K., Fu, Y., Patterson, K. R., and Binder, L. I. (2013) TOC1: characterization of a selective oligomeric Tau antibody. J. Alzheimers Dis. 37, 593-602
11. Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., and Holtzman, D. M. (2013) Anti-Tau antibodies that block Tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414
12. Castillo-Carranza, D. L., Gerson, J. E., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., and Kayed, R. (2014) Specific targeting of Tau oligomers in Htau mice prevents cognitive impairment and Tau toxicity following injection with brain-derived Tau oligomeric seeds. J. Alzheimers Dis. 40, S97-S111
13. Winderickx, J., Delay, C., De Vos, A., Klinger, H., Pellens, K., Vanhelmont, T., Van Leuven, F., and Zabrocki, P. (2008) Protein folding diseases and neurodegeneration: lessons learned from yeast. Biochim. Biophys. Acta 1783, 1381-1395
14. D'Angelo, F., Vignaud, H., Di Martino, J., Salin, B., Devin, A., Cullin, C., and Marchal, C. (2013) A yeast model for amyloid-β aggregation exemplifies the role of membrane trafficking and PICALM in cytotoxicity. Dis. Model. Mech. 6, 206-216
15. Treusch, S., Hamamichi, S., Goodman, J. L., Matlack, K. E., Chung, C. Y., Baru, V., Shulman, J. M., Parrado, A., Bevis, B. J., Valastyan, J. S., Han, H., Lindhagen-Persson, M., Reiman, E. M., Evans, D. A., Bennett, D. A., Olofsson, A., DeJager, P. L., Tanzi, R. E., Caldwell, K. A., Caldwell, G. A., and Lindquist, S. (2011) Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 334, 1241-1245
16. De Vos, A., Anandhakumar, J., Van den Brande, J., Verduyckt, M., Franssens, V., Winderickx, J., and Swinnen, E. (2011) Yeast as a model system to study tau biology. Int. J. Alzheimers Dis. 2011, 428970
17. Vandebroek, T., Terwel, D., Vanhelmont, T., Gysemans, M., Van Haesendonck, C., Engelborghs, Y., Winderickx, J., and Van Leuven, F. (2006) Microtubule binding and clustering of human Tau-4R and Tau-P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3β or Cdk5. J. Biol. Chem. 281, 25388-25397
18. Vandebroek, T., Vanhelmont, T., Terwel, D., Borghgraef, P., Lemaire, K., Snauwaert, J., Wera, S., Van Leuven, F., and Winderickx, J. (2005) Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast. Biochemistry 44, 11466-11475
19. Vanhelmont, T., Vandebroek, T., De Vos, A., Terwel, D., Lemaire, K., Anandhakumar, J., Franssens, V., Swinnen, E., Van Leuven, F., and Winderickx, J. (2010) Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast. FEMS Yeast Res. 10, 992-1005
20. Kato, Y., Jin, G., Kuan, C. T., McLendon, R. E., Yan, H., and Bigner, D. D. (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem. Biophys. Res. Commun. 390, 547-551
21. Lippens, G., Wieruszeski, J. M., Leroy, A., Smet, C., Sillen, A., Buée, L., and Landrieu, I. (2004) Proline-directed random-coil chemical shift values as a tool for the NMR assignment of the tau phosphorylation sites. Chembiochem 5, 73-78
22. Gottschalk, P. G., and Dunn, J. R. (2005) The five-parameter logistic: a characterization and comparison with the four-parameter logistic. Anal. Biochem. 343, 54-65
23. Schindowski, K., Bretteville, A., Leroy, K., Bégard, S., Brion, J. P., Hamdane, M., and Buée, L. (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 169, 599-616
24. Delacourte, A., and Defossez, A. (1986) Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. J. Neurol. Sci. 76, 173-186
25. McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Jr., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., and Phelps, C. H. (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269
26. Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J. M., Brun, A., and Hofman, A. (1993) Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 43, 250-260
27. Büttner, S., Delay, C., Franssens, V., Bammens, T., Ruli, D., Zaunschirm, S., de Oliveira, R. M., Outeiro, T. F., Madeo, F., Buée, L., Galas, M. C., and Winderickx, J. (2010) Synphilin-1 enhancesα-synuclein aggregation in yeast and contributes to cellular stress and cell death in a Sir2-dependent manner. PLoS One 5, e13700
28. Rösner, H., Rebhan, M., Vacun, G., and Vanmechelen, E. (1994) Expression of a paired helical filament tau epitope in embryonic chicken central nervous system. Neuroreport 5, 1164-1166
29. Goedert, M., Jakes, R., Crowther, R. A., Cohen, P., Vanmechelen, E., Vandermeeren, M., and Cras, P. (1994) Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem. J. 301, 871-877
30. Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjögren, M., Andreasen, N., and Blennow, K. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 49-52
31. Bhaskar, K., Hobbs, G. A., Yen, S. H., and Lee, G. (2010) Tyrosine phosphorylation of tau accompanies disease progression in transgenic mouse models of tauopathy. Neuropathol. Appl. Neurobiol. 36, 462-477
32. Amniai, L., Lippens, G., and Landrieu, I. (2011) Characterization of the AT180 epitope of phosphorylated Tau protein by a combined nuclear magnetic resonance and fluorescence spectroscopy approach. Biochem. Biophys. Res. Commun. 412, 743-746
33. Kawarabayashi, T., Shoji, M., Younkin, L. H., Wen-Lang, L., Dickson, D. W., Murakami, T., Matsubara, E., Abe, K., Ashe, K. H., and Younkin, S. G. (2004) Dimeric amyloidβ protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 24, 3801-3809
34. Sergeant, N., Sablonnière, B., Schraen-Maschke, S., Ghestem, A., Maurage, C. A., Wattez, A., Vermersch, P., and Delacourte, A. (2001) Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum. Mol. Genet. 10, 2143-2155
35. Olsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., and Blennow, K. (2005) Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336-345
36. Sjögren, M., Davidsson, P., Gottfries, J., Vanderstichele, H., Edman, A., Vanmechelen, E., Wallin, A., and Blennow, K. (2001) The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement. Geriatr. Cogn. Disord. 12, 257-264
37. Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., and Hansson, O. (2010) Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J. Alzheimers Dis. 21, 1119-1128
38. Buerger, K., Ewers, M., Andreasen, N., Zinkowski, R., Ishiguro, K., Vanmechelen, E., Teipel, S. J., Graz, C., Blennow, K., and Hampel, H. (2005) Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 65, 1502-1503
39. Buerger, K., Ewers, M., Pirttilä, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., and Hampel, H. (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041
40. Cowan, C. M., and Mudher, A. (2013) Are tau aggregates toxic or protective in tauopathies? Front. Neurol. 4, 114
41. Iqbal, K., Gong, C. X., and Liu, F. (2013) Hyperphosphorylation-induced tau oligomers. Front. Neurol. 4, 112
42. Gerson, J. E., and Kayed, R. (2013) Formation and propagation of tau oligomeric seeds. Front. Neurol. 4, 93
43. Dinkel, P. D., Siddiqua, A., Huynh, H., Shah, M., and Margittai, M. (2011) Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. Biochemistry 50, 4330-4336
44. Guo, J. L., and Lee, V. M. (2011) Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286, 15317-15331
45. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muoz, M. J., Jackson, G. R., and Kayed, R. (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039-10041
46. Wille, H., Drewes, G., Biernat, J., Mandelkow, E. M., and Mandelkow, E. (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J. Cell Biol. 118, 573-584
47. Barghorn, S., and Mandelkow, E. (2002) Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments. Biochemistry 41, 14885-14896
48. Lin, Y. T., Cheng, J. T., Liang, L. C., Ko, C. Y., Lo, Y. K., and Lu, P. J. (2007) The binding and phosphorylation of Thr231 is critical for Tau's hyperphosphorylation and functional regulation by glycogen synthase kinase 3β. J. Neurochem. 103, 802-813
49. Jeganathan, S., Hascher, A., Chinnathambi, S., Biernat, J., Mandelkow, E. M., and Mandelkow, E. (2008) Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J. Biol. Chem. 283, 32066-32076
50. Jeganathan, S., von Bergen, M., Brutlach, H., Steinhoff, H. J., and Mandelkow, E. (2006) Global hairpin folding of tau in solution. Biochemistry 45, 2283-2293
51. Kanaan, N. M., Morfini, G. A., LaPointe, N. E., Pigino, G. F., Patterson, K. R., Song, Y., Andreadis, A., Fu, Y., Brady, S. T., and Binder, L. I. (2011) Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J. Neurosci. 31, 9858-9868
52. LaPointe, N. E., Morfini, G., Pigino, G., Gaisina, I. N., Kozikowski, A. P., Binder, L. I., and Brady, S. T. (2009) The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J. Neurosci. Res. 87, 440-451
53. Kanaan, N. M., Morfini, G., Pigino, G., LaPointe, N. E., Andreadis, A., Song, Y., Leitman, E., Binder, L. I., and Brady, S. T. (2012) Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol. Aging 10.1016/j.neurobiolaging.2011.06.006
54. Gamblin, T. C., Berry, R. W., and Binder, L. I. (2003) Tau polymerization: role of the amino terminus. Biochemistry 42, 2252-2257
55. Sahara, N., Lewis, J., DeTure, M., McGowan, E., Dickson, D. W., Hutton, M., and Yen, S. H. (2002) Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J. Neurochem. 83, 1498-1508
56. Galván, M., David, J. P., Delacourte, A., Luna, J., and Mena, R. (2001) Sequence of neurofibrillary changes in aging and Alzheimer's disease: a confocal study with phospho-tau antibody, AD2. J. Alzheimers Dis. 3, 417-425
57. Kimura, T., Ono, T., Takamatsu, J., Yamamoto, H., Ikegami, K., Kondo, A., Hasegawa, M., Ihara, Y., Miyamoto, E., and Miyakawa, T. (1996) Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia 7, 177-181
58. Mondragón-Rodríguez, S., Perry, G., Luna-Muñoz, J., Acevedo-Aquino, M. C., and Williams, S. (2014) Phosphorylation of tau protein at sites Ser 396-404 is one of the earliest events in Alzheimer's disease and Down syndrome. Neuropathol. Appl. Neurobiol. 40, 121-135
59. Jicha, G. A., Lane, E., Vincent, I., Otvos, L., Jr., Hoffmann, R., and Davies, P. (1997) A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J. Neurochem. 69, 2087-2095
60. Haroutunian, V., Davies, P., Vianna, C., Buxbaum, J. D., and Purohit, D. P. (2007) Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol. Aging 28, 1-7
61. Luna-Muñoz, J., Chávez-Macías, L., García-Sierra, F., and Mena, R. (2007) Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J. Alzheimers Dis. 12, 365-375
62. Weaver, C. L., Espinoza, M., Kress, Y., and Davies, P. (2000) Conformational change as one of the earliest alterations of tau in Alzheimer's disease. Neurobiol. Aging 21, 719-727
63. Gendreau, K. L., and Hall, G. F. (2013) Tangles, toxicity, and Tau secretion in AD: new approaches to a vexing problem. Front. Neurol. 4, 160
64. Caillierez, R., Bégard, S., Lécolle, K., Deramecourt, V., Zommer, N., Dujardin, S., Loyens, A., Dufour, N., Aurégan, G., Winderickx, J., Hantraye, P., Déglon, N., Buée, L., and Colin, M. (2013) Lentiviral delivery of the human wild-type tau protein mediates a slow and progressive neurodegenerative tau pathology in the rat brain. Mol. Ther. 21, 1358-1368
65. Dujardin, S., Lécolle, K., Caillierez, R., Bégard, S., Zommer, N., Lachaud, C., Carrier, S., Dufour, N., Aurégan, G., Winderickx, J., Hantraye, P., Déglon, N., Colin, M., and Buée, L. (2014) Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol. Commun. 2, 14
66. Meredith, J. E., Jr., Sankaranarayanan, S., Guss, V., Lanzetti, A. J., Berisha, F., Neely, R. J., Slemmon, J. R., Portelius, E., Zetterberg, H., Blennow, K., Soares, H., Ahlijanian, M., and Albright, C. F. (2013) Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease. PLoS One 8, e76523